Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study
| Autor: | João H. Romaldini, Kioko Takei, Marco Aurélio Ferreira Federige, Ana Beatriz Pinotti Pedro Miklos, Evandro S. Portes, Marcia Kiyomi Koike |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Graves' disease selenoprotein P chemistry.chemical_element lcsh:Medicine 030209 endocrinology & metabolism Hashimoto Disease Serum selenium lcsh:Diseases of the endocrine glands. Clinical endocrinology Thyroiditis Graves' ophthalmopathy 03 medical and health sciences Selenium 0302 clinical medicine Hashimoto's thyroiditis Internal medicine Graves’ ophthalmopathy Selenoprotein P Medicine Humans Aged 030109 nutrition & dietetics lcsh:RC648-665 business.industry Spectrophotometry Atomic Thyroid lcsh:R Case-control study Middle Aged medicine.disease Graves Disease Graves Ophthalmopathy medicine.anatomical_structure Endocrinology Cross-Sectional Studies chemistry Case-Control Studies Disease Progression Female business Graves’ disease Biomarkers |
| Zdroj: | Archives of Endocrinology and Metabolism, Vol 61, Iss 6, Pp 600-607 Archives of Endocrinology and Metabolism v.61 n.6 2017 Arquivos de Endocrinologia e Metabolismo Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM Archives of Endocrinology and Metabolism, Volume: 61, Issue: 6, Pages: 600-607, Published: DEC 2017 |
| ISSN: | 2359-4292 |
| Popis: | Objective: Selenium (Se) supplementation has been used to help prevent the progression of Graves’ ophthalmopathy (GO) and autoimmune thyroid diseases (AITD) patients. We investigated Se serum and selenoprotein P (SePP) levels in Graves’ disease (GD) with and without GO, Hashimoto's thyroiditis (HT) patients and in 27 control individuals (C). Subjects and methods: We studied 54 female and 19 male patients: 19 with GD without GO, 21 GD with GO, 14 with HT and 19 with HT+LT4. Se values were measured using graphite furnace atomic absorption spectrophotometry. Serum SePP levels were measured by ELISA. Results: Median Se levels were similar among all groups; GD patients: 54.2 (46.5-61.1 μg/L), GO: 53.6 (43.5-60.0 μg/L), HT: 51.9 (44.6-58.5 μg/L), HT+LT4 54.4 (44-63.4) and C group patients: 56.0 (52.4-61.5 μg/L); P = 0.48. However, serum SePP was lower in GO patients: 0.30 (0.15-1.05 μg/mL) and in HT patients: 0.35 (0.2-1.17 μg/mL) compared to C group patients: 1.00 (0.564.21 μg/mL) as well as to GD patients: 1.19 (0.62-2.5 μg/mL) and HT+LT4 patients: 0.7 (0,25-1.95); P = 0.002. Linear regression analysis showed a significant relationship between SePP and TPOAb values (r = 0.445, R2 = 0.293; P < 0.0001). Multiple regression analysis found no independent variables related to Se or SePP. Conclusion: A serum Se concentration was lower than in some other countries, but not significantly among AITD patients. The low serum SePP levels in GO and HT patients seems to express inflammatory reactions with a subsequent increase in Se-dependent protein consumption remains unclear. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|